OutPost Bio Raises €2.9M Pre-Seed to Make Human Microbiology Computable

The human microbiome — the vast community of microorganisms colonising the gut, skin, and other organs — has long been recognised as a critical but poorly understood variable in human health. Despite its influence on how drugs are metabolised, how pathogens spread, and how the body responds to treatment, the microbiome has remained computationally intractable. That gap is what London-based OutPost Bio is setting out to close.

The biotech startup has raised €2.9 million (approximately $3.5 million) in a pre-seed funding round to accelerate its platform for making human microbiology computable at scale. The round was co-led by Merantix Capital and Seedcamp, with participation from OpenSeed VC, Defined, and a group of strategic family offices and angel investors.

A Closed Loop Between the Lab and the Algorithm

At the heart of OutPost Bio’s approach is what it calls the Lab-in-the-Loop platform — a system that integrates automated experimentation with machine learning in a continuous feedback cycle. Rather than treating laboratory work and modelling as sequential activities, the platform routes insights from ML models directly back into the experimental design, accelerating the generation of functional biological data.

The result is a proprietary dataset of human-derived microbial interactions that, the company argues, goes far beyond the correlational evidence available in existing literature. Microbial communities can dramatically alter drugs and other interventions, yet this layer has been largely ignored because the data has not existed at scale. For the first time, the platform aims to move beyond correlations to reveal causal pathways.

For pharmaceutical and biotech partners, this translates into a concrete set of applications: predicting microbe-mediated drug metabolism, identifying potential toxicity signals earlier in development, and building the regulatory evidence needed to bring safer formulations to market.

The Team Behind the Science

OutPost Bio was founded in 2025 by Dr Jenny Yang and Alex Merwin. Dr Yang — an Oxford PhD and former Marie Curie Fellow with a background in clinical machine learning — serves as CEO, bringing a rare combination of bench science expertise and applied AI experience to the role. Merwin, the company’s COO, previously led growth for health and bio startups at Amazon Web Services.

The founding team is further strengthened by Dr Heidi Arjes (VP of R&D, with two decades of microbiology experience across academia and industry), Dr Saif Ur-Rehman (Director of Data Engineering, formerly a founding engineer at Basecamp Research), and Dr Neythen Treloar (Principal ML Scientist, with expertise in microbial foundation models).

Investor Confidence in a Fast-Growing Market

The round reflects growing investor interest in precision microbiome science. Europe’s human microbiome market was valued at approximately $290 million in 2025 and is forecast to reach $1.31 billion by 2031, advancing at a compound annual rate of 28.6%. European research institutions conducted more than 820 microbiome-based clinical studies in 2025, led by Germany, the United Kingdom, and France.

Merantix Capital — a Berlin-based deep tech venture fund focused on AI-driven life sciences — and Seedcamp, one of Europe’s most prolific seed investors, co-leading the round positions OutPost Bio at the intersection of two investable themes: AI-accelerated drug discovery and the microbiome’s mounting clinical relevance. Additional backing from OpenSeed VC and Defined brings further domain expertise in biotech and digital health.

The pre-seed capital will be deployed to expand the Lab-in-the-Loop platform, scale proprietary data generation, and deepen partnerships with pharmaceutical companies seeking to integrate microbial modelling into their development pipelines.

Redefining Microbiology as a Computational Layer

The implications for pharmaceutical R&D are significant. Historically, the microbiome has been treated as a confounding variable rather than a predictable parameter. If OutPost Bio can deliver consistent, causal models of microbial behaviour, the practical benefit for drug developers is earlier and less costly de-risking of clinical candidates — particularly in areas such as oral drug metabolism, gut-delivered therapeutics, and microbiome-targeted interventions.

The company’s dual presence in London and Boston also positions it well to serve European and US pharma markets simultaneously, giving partners on both sides of the Atlantic access to the platform’s data and modelling capabilities.